Sendas Distribuidora (ASAI3) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
23 Nov, 2025Executive summary
Revenue reached R$21 billion in Q2, up 7.2% year-over-year, with stable market share and same-store sales growth of 4.6% despite persistent trade-down trends and consumer pressure from high interest rates and inflation.
EBITDA margin pre-IFRS16 improved by 0.3 p.p. year-over-year to 5.7%, driven by store maturity, innovation, and strict expense controls.
Free cash flow before interest payments reached R$2.7 billion in the last 12 months, reflecting lower investment cycles, disciplined working capital management, and strong cash generation.
Net income pre-IFRS16 rose 60% to R$264 million, aided by operational efficiency, tax credits, and ongoing debt reprofiling.
Recognized as the most valuable brand in food retail and renewed GPTW certification for the 4th year.
Financial highlights
EBITDA margin pre-IFRS16 reached 5.7% (+0.3 p.p. YoY); EBITDA pre-IFRS16 rose by R$0.5 billion LTM.
Net income pre-IFRS16 grew 60% to R$264 million; net margin improved by 0.5 p.p. to 1.4%.
90% of EBITDA converted to free cash flow over the last 12 months.
Net debt reduced by R$200 million year-over-year, with leverage dropping 0.48x to 3.17x.
Operational cash generation reached R$3.9 billion in the last 12 months.
Outlook and guidance
Guidance targets net debt/EBITDA of 2.6x by year-end 2025, with financial net debt at about 2x.
Expansion plan targets 10 new stores in 2025 and 10 in 2026, with CAPEX between R$1.0–1.2 billion for 2025.
Expectation for recovery in same-store sales, focusing on new projects and increasing share of wallet.
Private label and new product categories to drive margin improvement and competitiveness.
Latest events from Sendas Distribuidora
- Revenue up 5.2%, EBITDA margin 5.8%, leverage 2.56x, and free cash flow R$2.8B.ASAI3
Q4 202512 Feb 2026 - Revenue and EBITDA rose as leverage improved, with over 300 stores targeted for 2024.ASAI3
Q2 20241 Feb 2026 - Revenue and EBITDA up, leverage down, and expansion and deleveraging remain priorities.ASAI3
Q3 202415 Jan 2026 - Board size cut, compensation reduced, and new poison pill triggers reflect governance reforms.ASAI3
Status Update26 Dec 2025 - Record revenue, margin gains, and lower leverage defined 2024's strong performance.ASAI3
Q4 202411 Dec 2025 - Revenue up 7.8%, EBITDA margin at 5.5%, and leverage improved to 3.15x in Q1 2025.ASAI3
Q1 202519 Nov 2025 - Revenue, EBITDA margin, and free cash flow rose as leverage hit a multi-year low.ASAI3
Q3 202513 Nov 2025